What are the latest figures on the benign prostatic hyperplasia treatment market’s size and projected CAGR?
The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing awareness and screening initiatives, rising prevalence of BPH, increasing healthcare awareness, improving healthcare infrastructure, and growing elderly population.
The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, a growing number of geriatric patients, a rising availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Major trends in the forecast period include developing targeted therapies, integration of digital health solutions, innovation in surgical options, integration of 3D imaging for diagnosis, and innovation in patient-centered care models.
Get Your Free Sample of The Global Benign Prostatic Hyperplasia Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp
Which Market drivers have played a significant role in driving the benign prostatic hyperplasia treatment market?
The rise in adoption of minimally invasive surgeries is expected to propel the growth of the benign prostatic hyperplasia treatment market going forward. Minimally invasive surgeries are procedures that involve small incisions or no incisions at all, using specialized instruments to reduce recovery time, pain, and risk of complications. The rise in adoption of minimally invasive surgeries is driven by benefits such as shorter recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. Benign prostatic hyperplasia treatment through minimally invasive surgeries provides patients with reduced recovery times, lower risks of complications, and effective symptom relief, enhancing overall surgical outcomes. For instance, in September 2023, according to the American Society of Plastic Surgeons (ASPS), a US-based professional association, in 2022, a total of 23,672,269 cosmetic minimally invasive procedures were performed globally, including treatments such as neuromodulator injections, lip augmentation, and non-invasive skin tightening. Therefore, the rise in adoption of minimally invasive surgeries is driving the growth of the benign prostatic hyperplasia treatment market.
What are the key segments within the benign prostatic hyperplasia treatment market?
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report
Which key players are shaping the benign prostatic hyperplasia treatment market?
Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.
Which transformative trends will shape the benign prostatic hyperplasia treatment market landscape?
Major companies operating in the benign prostatic hyperplasia treatment market are prioritizing the development of innovative solutions, including minimally invasive procedures, to enhance patient outcomes and shorten recovery times. These procedures involve small or no incisions, minimizing trauma, pain, and complications while offering a faster recovery compared to traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a US-based medical device company, launched the UroLift System to treat benign prostatic hyperplasia. This system utilizes small permanent implants to reposition enlarged prostate tissue, offering significant symptom relief without the need for tissue removal, cutting, or heating. This outpatient treatment ensures rapid recovery, preserves sexual function, and delivers superior symptom relief compared to traditional BPH medications, with side effects typically resolving within two to four weeks.
How do regional factors impact the benign prostatic hyperplasia treatment market, and which region is the largest contributor?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Benign Prostatic Hyperplasia Treatment Market Report 2025 Offer?
The benign prostatic hyperplasia treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Benign prostatic hyperplasia (BPH) treatment refers to medical, minimally invasive, and surgical approaches used to manage the symptoms of an enlarged prostate. BPH is a common condition in aging men, leading to urinary issues such as frequent urination, weak stream, and incomplete bladder emptying.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
